Exploring immune responses in thyroid and colon cancer
Trained Immunity of Myeloid Cells and Their Progenitors in Patients With Non-medullary Thyroid Carcinoma and Colon Carcinoma
This study is testing how changes in certain immune cells might affect the outcomes for people with newly diagnosed thyroid and colon cancer, and whether training these cells can improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Radboud University Medical Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Nijmegen, Gelderland) |
| Trial ID | NCT05280379 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of innate immunity in the development of thyroid carcinoma and colon carcinoma. It aims to understand how tumor-induced changes in bone marrow myeloid progenitor cells affect patient outcomes and to identify potential therapeutic targets. The study will analyze the effects of agents that induce 'trained immunity' on these myeloid cells, with the hope of re-educating them to improve cancer treatment outcomes. The research focuses on newly diagnosed, therapy-naïve patients who are scheduled for conventional treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with newly diagnosed, therapy-naïve non-medullary thyroid carcinoma or colon carcinoma.
Not a fit: Patients with severe comorbidities, previous anti-cancer treatments, or those with conditions affecting the immune system may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to novel therapeutic strategies that enhance immune responses in cancer patients.
How similar studies have performed: While the concept of trained immunity is gaining interest, this specific approach in thyroid and colon carcinoma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years old and mentally competent * Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve * Planned to receive conventional treatment for the malignancy by surgery Exclusion Criteria: * Mentally incompetent * Pregnant or breastfeeding * Known inflammation or infectious disease or an immunosuppressive status * Using medication interfering with the immune system * Reduced platelets counts or other conditions associated with an increased risk of bleeding * Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas) * Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor * Serious psychiatric pathology * A self-reported alcohol consumption of \>21 units per week
Where this trial is running
Nijmegen, Gelderland
- RadboudUMC — Nijmegen, Gelderland, Netherlands (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.